Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kasuya, Takeshi ^a   Hori, Shin Ichiro ^a   Watanabe, Ayahisa ^a   Nakajima, Mado ^a   Gahara, Yoshinari ^a   Rokushima, Masatomo ^a   Yanagimoto, Toru ^a   Kugimiya, Akira ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID; OLIGONUCLEOTIDE; RIBONUCLEASE H; RIBONUCLEASE HI;

ANIMAL; C57BL MOUSE; GENE SILENCING; GENETICS; LIVER; MALE; METABOLISM; MOUSE;

ANIMALS; GENE SILENCING; LIVER; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RIBONUCLEASE H;

EID: 84979738435     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30377     Document Type: Article

References (53)

1. Crook, S. T. Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edition. (CRC Press, 2008).
2. Bennett, F. C., Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293 (2010).
3. Geary, R. S. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 5, 381-391 (2009).
4. Obika, S., Morio, K., Nanbu, D., Imanishi, T. Synthesis and conformation of 3?-O,4?-C-methyleneribonucleosides, novel bicyclic nucleoside analogues for 2?, 5?-linked oligonucleotide modification. Chem. Commun. 17, 1643-1644 (1997).
5. Koshkin, A. A. et al. LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54, 3607-3630 (1998).
6. Lundin, K. E. et al. Biological activity and biotechnological aspects of locked nucleic acids. Adv. Genet. 82, 47-107 (2013).
7. Swayze, E. E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700 (2007).
8. Turchi, J. J., Huang, L., Murante, R. S., Kim, Y., Bambara, R. A. Enzymatic completion of mammalian lagging-strand DNA replication. Proc. Natl. Acad. Sci. USA 91, 9803-9807 (1994).
9. Lazzaro, F. et al. RNase H and postreplication repair protect cells from ribonucleotides incorporated in DNA. Mol. Cell 45, 99-110 (2012).
10. Cerritelli, S. M. et al. Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice. Mol. Cell 11, 807-815 (2003).
11. Wu, H. et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 279, 17181-17189 (2004).
12. Yu, R. Z.et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2?-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinetics 48, 39-50 (2009).
13. Yu, R. Z. et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metabol. Dis. 35, 460-468 (2007).
14. Kastelein, J. J. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (2006).
15. FDA Briefing Document, Mipomersen Sodium Injection 200 mg/mL. NDA 203568 (2012).
16. EMA public assessment report, Questions and answers on the refusal of the marketing authorisation for Kynamro (Mipomersen Sodium)-Outcome of re-examination. EMA/177547/2013 (2013).
17. Stanton, R. et al. Chemical modification study of antisense gapmers. (2012) Nucleic Acid Ther 22, 344-559 (2009).
18. van Poelgeest, E. P. et al. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am. J. Kid. Dis. 62, 796-800 (2013).
19. Seth, P. P., Jazayeri, A., Yu, J., Allerson, C. R., Bhat, B., Swayze, E. E. Structure activity relationships of ?-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol. Ther.-Nucleic Acids 1, e47 (2012).
20. Seth, P. P. et al. Short antisense oligonucleotides with novel 2?-4? conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13 (2009).
21. Seth, P. P. et al. An exocyclic methylene group acts as a bio-isostere of the 2?-oxygen atom in LNA. J. Am. Chem. Socs. 132, 14942-14950 (2010).
22. Burel, S. A. et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 23, 213-227 (2013).
23. Egli, M. et al. Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3?-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J. Am. Chem. Soc. 133, 16642-16649 (2011).
24. Burdick, A. D. et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res. 42, 4882-4891 (2014).
25. Hagedorn, P. H. et al. Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther. 23, 302-310 (2013).
26. Kakiuchi-Kiyota, S. et al. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Toxicol. Sci. 138, 234-248 (2014).
27. Burel, S. A. et al. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res. 10.1093/nar/gkv1210 (2015).
28. Kassel, O., Herrlich, P. Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects. Mol. Cel. Endocrinol. 275, 13-29 (2007).
29. LI, L. O., Klett, E. L., Coleman, R. A. Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta. 1801, 246-251 (2010).
30. Lima, W. F. et al. Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem. 279, 36317-36326 (2004).
31. Lima, W. F. et al. Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol. 71, 83-91 (2007).
32. Nowotny, M. et al. Structure of human RNase H1 complexed with an RNA/DNA hybrid: Insight into HIV reverse transcription. Mol. Cell. 28, 264-276 (2007).
33. Reijns, M. A. M. et al. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome Integrity and development. Cell 149, 1008-1022 (2012).
34. Hiller, B. et al. Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J. Exp. Med. 8, 1419-1426 (2012).
35. Reijns, M. A. The structure of the human RNase H2 complex defines key interaction interfaces relevant to enzyme function and human disease. J. Biol. Chem. 286, 10530-10539 (2011).
36. Crow, Y. J. et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutie'res syndrome and mimic congenital viral brain infection. Nat. Genet. 38, 910-916 (2006).
37. Straarup, E. M. et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acid Res. 38, 7100-7111 (2010).
38. Dobie, K. W., Koller E. Inventors; Isis Pharmaceuticals, Inc., assignee. Antisense modulation of kinesin-like 1 expression. United States patent US 7,163,927. 2007 Jan 16. 39. Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958-16961 (2014).
39. Watanabe, A. et al. Comparative characterization of hepatic distribution and mRNA reduction of antisense oligonucleotides conjugated with triantennary N-acetyl galactosamine and lipophilic ligands targeting apolipoprotein B. J. Pharmacol. Exp. Ther. 10.1124/jpet.115.230300 (2016).
40. Suzuki, Y. et al. An upstream open reading frame and the context of the two AUG codons affect the abundance of mitochondrial and nuclear RNase H1. Mol. Cell. Biol. 30, 5123-5134 (2010).
41. Koczor, C. A., Torres, R. A., Lewis, W. The role of transporters in the toxicity of nucleoside and nucleotide analogus. Expert Opin. Drug Metab. Toxicol. 8, 665-676 (2012).
42. Kawai, T., Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
43. Krieg, A. M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549 (1995).
44. Kawabata, T. Functional alterations of liver innate immunity of mice with aging in response to CpG-oligodeoxynucleotide. Hepatology 48, 1586-1597 (2008).
45. Senn, J. J., Burel, S., Henry, S. P. Non-CpG-containing antisense 2?-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation. J. Phrmacol. Exp. Ther. 314, 972-979 (2005).
46. Burel, S. A. et al. Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiationassociated gene 5-dependent induction of Type I interferon response. J. Phrmacol. Exp. Ther. 342, 150-162 (2012)
47. Vollmer, J. et al. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 14, 23-31 (2004).
48. Watts, L. M. et al. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54, 1846-1853 (2005).
49. Liang, Y. et al. Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice. Metabolism 54, 848-855 (2005).
50. Li, O. L. et al. Liver-specific loss of long chain acyl-coA synthetase-1 decreases triacylglycerol synthesis and ?-oxidation and alters phospholipid fatty acid composition. J. Biol. Chem. 284, 27816-27826 (2009).
51. Kamola, P. J. et al. In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res. 43, 8638-8650 (2015).
52. Lindow, M. et al. Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat. Biotechnol. 30, 920-923 (2012).
53. Sintim, H. O., Kool, E. T. Enhanced base pairing and replication efficiency of thiothymidines, expanded-size variants of thymidine. J. Am. Chem. Soc. 128, 396-397 (2006).